story of the week
ESMO 2020: Adjuvant Nivolumab Offers Novel Treatment Advance in Esophageal/Gastroesophageal Junction Cancer
CheckMate 577 has shown improved disease-free survival with nivolumab; it is ongoing, to establish overall survival outcomes
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.